



Cordlife Partners US-Based PlumCare to Offer Genetic Screening for Disease Management and Prevention

- Cordlife has entered a partnership with PlumCare LLC, a US-based company founded by two eminent clinical geneticists.
- PlumCare™ DNA Advisor, a genetic testing service will soon be launched by Cordlife under their Genscreen brand, to help families in Asia identify gene variants associated with increased risk of developing inherited conditions such as breast and ovarian cancer.
- The global DNA testing market is estimated to reach USD10.04 billion by 2020. In Asia Pacific, high growth is expected due to developments in health infrastructure coupled with large population suffering from chronic and acute conditions.

SINGAPORE, 26 February 2018 – Cordlife Group Limited, a Singapore Exchange mainboard listed consumer healthcare company, (“**Cordlife**”, and together with its subsidiaries, the “**Group**”) has entered into a partnership with PlumCare LLC (“**PlumCare**”), a US-based company founded by two eminent clinical geneticists, to offer a genetic testing service to help families in Asia identify gene variants associated with increased risk of developing inherited conditions such as breast and ovarian cancer.

Known as PlumCare™ DNA Advisor, the test combines whole exome sequencing and analysis as well as expert curation of clinical genetics information to allow families manage their well-being across generations--with a focus on children. Exome is the protein coding region of the human genome, where most disease-causing variants are located. By targeting at this region using whole exome sequencing, comprehensive results can be made available to the family at a more affordable rate than whole genome sequencing.

The service requires participation from at least three family members to enable better counselling and insights. PlumCare™ DNA Advisor will provide insights for children on seven categories of conditions including cancer, cardiac, hearing, connective tissue, metabolic, seizures, and response to anaesthesia. Adults will receive reports focused on cancer, cardiac, connective tissue, metabolic and response to anaesthesia. The testing and analysis will be performed by CAP-accredited laboratories in the United States.



PlumCare™ DNA Advisor is the brainchild of Dr Petros Tsipouras, a specialist in clinical genetics and an adjunct professor at Yale University School of Medicine, and Dr Paul Billings, a specialist in genomic medicine. The team at PlumCare is also made up of highly experienced scientific and medical informatics experts associated with Harvard and Yale Universities.

Based on a recent study, the global DNA testing market is estimated to reach USD10.04 billion by 2022.¹ In the Asia Pacific region, the industry is anticipated to witness high growth due to developments in healthcare infrastructure coupled with large target population suffering from chronic and acute conditions.

“We are excited to work with PlumCare to offer their highly reliable genetic testing services in Asia. Test findings can be used to determine patterns and identify potential health risks for everyone in the family. Such an approach can enable families to make more informed healthcare and lifestyle choices. At the same time, this diagnostic offering further bolsters Cordlife’s income and cash flow potential. It accelerates our effort to continue to diversify our revenue streams by providing more new products and services to our large installed client base, as well as future clients,” said Michael Weiss, Group CEO and Executive Director of Cordlife.

“The opportunity to provide high quality, evolving advice and support to families around the world with best in class testing, interactive databases and collaborations with world-renowned providers is PlumCare’s mission which this partnership now brings to Asia,” said Dr. Tsipouras, CEO and Co-Founder of PlumCare.

PlumCare™ DNA Advisor will soon be launched and marketed by Cordlife under the Genscreen brand. Other diagnostics services in their portfolio currently include non-invasive prenatal testing, urine-based metabolic screening for newborns, and paediatric vision screening for children aged six months to six years.

End

¹ DNA Testing Market Size To Reach USD 10.04 Billion By 2022. Grand View Research website.
<https://www.grandviewresearch.com/press-release/global-dna-testing-market> Accessed on 8 February 2018.



Media & Investor Contact Information

WeR1 Consultants Pte Ltd

3 Phillip Street, #12-01, Royal Group
Building
Singapore 048693
Tel: (65) 6737 4944

Frankie Ho – frankieho@wer1.net

Grace Yew – graceyew@wer1.net

Afina Kong – afinakong@wer1.net

About Cordlife Group Limited (Bloomberg: CLGL; Reuters: CORD.SI)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a leading provider of cord blood, cord tissue and umbilical cord lining banking services in Asia.

As a consumer healthcare company catering to, among others, the mother and child segment, Cordlife has the largest market share among private cord blood banks in Singapore, Hong Kong, the Philippines and Indonesia. It is among the Top 3 market leaders in India and Malaysia. Cordlife is also the first Singapore private cord blood bank in Myanmar and Vietnam.

Cordlife’s cord blood processing and cryopreservation facility in Singapore is one of only six private cord blood banks in the world to be dually accredited by AABB and FactNetcord, two of the world’s gold standards for cord blood banking. The Group’s majority-owned Hong Kong Screening Centre Limited and Cordlife Sciences (India) Pvt Ltd have also received accreditation from the College of American Pathologists, which only recognises facilities that meet or exceed the highest standards in laboratory services. Cordlife has been listed on the mainboard of Singapore Exchange since March 2012. For more information, visit <http://cordlife.listedcompany.com>

About PlumCare

PlumCare was created for families by two eminent clinical geneticists, Dr. Paul Billings and Dr. Petros Tsiouras. PlumCare™ DNA Advisor provides access to the progress in genetics through DNA testing, analysis, insights, and learnings from world-class research. The service combines the simplicity of saliva-based whole exome DNA testing, data from all participating family members (family trios or more), family medical history, external research and analysis. With a subscription, the service provides ongoing monitoring of scientific advances with annual reports and notifications. The insights, advice and access to local specialists help families to manage unexpected or chronic illnesses and their well-being across generations for a lifetime. Learn more at www.plumcarehealth.com.